查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1833551

2032 年先进製药市场预测：按配方类型、药物类型、治疗领域、技术、最终用户和地区进行的全球分析

Advanced Drug Formulation Market Forecasts to 2032 - Global Analysis By Formulation Type (Oral, Injectable, Topical, Transdermal, Inhalation, Nasal, and Implantable), Drug Type, Therapeutic Area, Technology, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，全球先进製药市场预计在 2025 年达到 1.9 兆美元，到 2032 年将达到 2.9 兆美元，预测期内的复合年增长率为 6.1%。

先进製剂涉及开发有效且安全地递送药物化合物的创新方法。这包括缓释性、标靶递送和增溶等技术。这些製剂可增强疗效、减少给药频率并提高患者遵从性。所用技术包括脂质体、微球、奈米颗粒和经皮系统。此过程整合了药物动力学、材料科学和工程学，以优化口服、注射和局部等各种给药途径的药物稳定性、吸收和生物有效性。

据Pharma Intelligence称，先进的配方可提高药物的稳定性、溶解度和输送能力，从而实现缓释性、奈米封装和个人化医疗方面的突破。

慢性病增多

在全球范围内，癌症、心血管疾病和糖尿病等慢性疾病的发生率不断上升，推动了对先进药物製剂的需求。这些疾病需要创新的治疗方案，以提高生物有效性、确保控制释放并改善患者依从性。在对标靶性和个人化治疗方法的需求推动下，製药公司正在大力投资先进的製剂技术。这种势头正在改变药物输送方式，推动市场成长，并强化市场的长期扩张轨迹。

研发和监管成本高

儘管成长前景光明，但由于高昂的研发成本和复杂的法律规范，市场面临巨大的限制。先进的製剂通常涉及复杂的输送系统、生物製药整合和奈米技术，推高了製造成本。此外，监管核准需要大量的临床试验，这延长了审批週期并增加了不确定性。这些财务和合规负担尤其影响小型生技公司，限制了它们的扩张能力。因此，成本和核准障碍对创新製剂的全球应用构成了重大挑战。

儿科和老年用药製剂快速成长

针对儿科和老年族群的先进製剂需求日益增长，蕴藏着巨大的商机。由于吞嚥障碍、代谢差异和服药依从性问题，这些病患小组通常难以适应传统剂型。受这些需求的驱动，口溶锭、咀嚼片和缓释系统等创新製剂正日益受到青睐。製药公司正在积极利用以患者为中心的製剂策略来拓展这一细分市场。这些由人口结构驱动的变化预计将加速药物的采用和市场成长。

儿童和老年人申请数量快速成长

市场面临的一大威胁是专利频繁到期，这为学名药製造商的强势进入铺平了道路。这加剧了价格竞争，降低了品牌药的利润率。此外，学名药由于价格低廉，尤其是在成本敏感的地区，往往能迅速被接受。这种动态迫使创新企业持续投资于产品线开发。如果无法透过创新配方实现差异化，品牌药公司可能会失去市场份额，并威胁到其长期永续性。

COVID-19的影响：

新冠疫情对先进製药市场产生了双重影响。一方面，全球供应链中断和临床试验延迟阻碍了研发进程。另一方面，这场危机加速了对创新药物递送方法的需求，尤其是疫苗和抗病毒疗法。各公司以前所未有的速度采用mRNA製剂和新型递送系统，树立了新的效率标准。这段变革时期凸显了先进製药在应对全球卫生紧急情况及其他领域的重要性。

预计口腔护理市场在预测期内将占据最大份额

预计口服药物领域将在预测期内占据最大的市场份额，这得益于患者用药便利性、高依从性和成本效益。缓释片、口溶锭和奈米口服药物等先进剂型正在巩固该领域的市场地位。慢性病口服药物的激增进一步推动了该领域的应用。製药公司正优先考虑该领域的技术创新，以最大限度地提高治疗效果。因此，预计口服药物领域将在未来几年占据最大的市场份额。

生物製药领域预计将在预测期内以最高的复合年增长率成长

受标靶治疗、单株抗体和细胞疗法需求成长的推动，生技药品领域预计将在预测期内实现最高成长率。这些复杂的分子需要复杂的配方策略来维持稳定性、有效性和控制释放。在生物技术和精准医疗的推动下，生技药品领域正获得强劲发展动能。对生物相似药和下一代生物生技药品的持续投资预计将进一步推动其扩张。因此，预计该领域将在预测期内实现最高的复合年增长率。

占比最大的地区：

预计亚太地区将在预测期内占据最大市场份额，这得益于医疗保健支出的不断增长、患者人数的庞大以及製药业的快速扩张。中国、印度和日本等国家正在加强其研发基础设施，以吸引全球投资。此外，文明病的日益普及以及政府的支持政策正在推动先进製剂的采用。综合来看，这些因素使亚太地区成为先进製剂领域的主导者。

复合年增长率最高的地区：

北美地区凭藉其强大的创新能力、先进的医疗基础设施以及支持新药研发的健全法律规范，预计将在预测期内呈现最高的复合年增长率。该地区汇聚了许多大型製药和生物技术公司，致力于投资下一代药物传输技术。此外，生技药品需求的不断增长，加上慢性病的高发生率，正在加速其应用。在优惠的保险报销政策的推动下，高端疗法的快速普及也推动了成长。因此，北美将成为成长最快的区域市场。

免费客製化服务

此报告的订阅者可以使用以下免费自订选项之一：

  • 公司简介
    • 对最多三家其他市场公司进行全面分析
    • 主要企业的SWOT分析（最多3家公司）
  • 区域细分
    • 根据客户兴趣对主要国家进行的市场估计、预测和复合年增长率（註：基于可行性检查）
  • 竞争基准化分析
    • 根据产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第一章执行摘要

第二章 前言

  • 概述
  • 相关利益者
  • 调查范围
  • 调查方法
    • 资料探勘
    • 数据分析
    • 数据检验
    • 研究途径
  • 研究材料
    • 主要研究资料
    • 次级研究资讯来源
    • 先决条件

第三章市场走势分析

  • 驱动程式
  • 抑制因素
  • 机会
  • 威胁
  • 技术分析
  • 最终用户分析
  • 新兴市场
  • COVID-19的影响

第四章 波特五力分析

  • 供应商的议价能力
  • 买方的议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争对手之间的竞争

5. 全球先进製药市场（按製剂类型）

  • 口服
  • 注射
  • 外用
  • 经皮
  • 吸入
  • 鼻腔
  • 嵌入式

6. 全球先进製药市场（依药物类型）

  • 小分子
  • 生物製药
  • 疫苗
  • 胜肽
  • 基于核酸的
  • 生物相似药
  • 学名药

7. 全球先进製药市场（依治疗领域）

  • 肿瘤学
  • 心血管系统
  • 神经病学
  • 感染疾病
  • 免疫学
  • 内分泌学
  • 罕见疾病

8. 全球先进製药市场（按技术）

  • 奈米科技
  • 脂质体递送
  • 持续释放
  • 控释
  • 定向投放
  • 固体分散体

9. 全球先进製药市场（依最终用户划分）

  • 医院
  • 製药公司
  • 生技公司
  • 研究办公室
  • 诊所
  • 合约研究组织
  • 学术机构

第 10 章全球先进製药市场（按地区）

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 其他欧洲国家
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 其他南美
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东和非洲地区

第十一章 重大进展

  • 协议、伙伴关係、合作和合资企业
  • 收购与合併
  • 新产品发布
  • 业务扩展
  • 其他关键策略

第十二章 公司概况

  • AstraZeneca
  • Bristol-Myers Squibb
  • Eli Lilly
  • Gilead Sciences
  • Merck & Co.
  • Novartis
  • Pfizer
  • AbbVie
  • Boehringer Ingelheim
  • F. Hoffmann-La Roche
  • Bayer
  • Sanofi
  • Amgen
  • Celgene
  • Johnson & Johnson
  • Regeneron Pharmaceuticals
Product Code: SMRC31384

According to Stratistics MRC, the Global Advanced Drug Formulation Market is accounted for $1.9 trillion in 2025 and is expected to reach $2.9 trillion by 2032 growing at a CAGR of 6.1% during the forecast period. Advanced drug formulation involves the development of innovative methods to deliver pharmaceutical compounds effectively and safely. It includes techniques like sustained release, targeted delivery, and solubility enhancement. These formulations improve therapeutic efficacy, reduce dosing frequency, and enhance patient compliance. Technologies used include liposomes, microspheres, nanoparticles, and transdermal systems. The process integrates pharmacokinetics, material science, and engineering to optimize drug stability, absorption, and bioavailability across various routes of administration, including oral, injectable, and topical.

According to Pharma Intelligence, advanced formulations enhance drug stability, solubility, and delivery, enabling extended-release, nanoencapsulation, and personalized medicine breakthroughs.

Market Dynamics:

Driver:

Increasing prevalence of chronic diseases

The rising global burden of chronic illnesses such as cancer, cardiovascular disorders, and diabetes is driving strong demand for advanced drug formulations. These conditions require innovative therapeutic solutions that enhance bioavailability, ensure controlled release, and improve patient adherence. Fueled by the need for targeted and personalized treatment approaches, pharmaceutical companies are investing heavily in advanced formulation technologies. This momentum is reshaping drug delivery practices, fostering growth, and strengthening the market's long-term expansion trajectory.

Restraint:

High R&D and regulatory costs

Despite promising growth, the market faces significant restraints from high research and development expenditures and complex regulatory frameworks. Advanced formulations often involve sophisticated delivery systems, biologics integration, and nanotechnology, which escalate production costs. Additionally, regulatory approvals demand extensive clinical trials, prolonging timelines and raising uncertainty. These financial and compliance burdens particularly impact smaller biotech firms, limiting their ability to scale. Consequently, cost and approval barriers pose notable challenges to wider adoption of innovative drug formulations globally.

Opportunity:

Pediatric and geriatric applications surge

A promising opportunity lies in the growing demand for advanced formulations tailored to pediatric and geriatric populations. These patient groups often face difficulties with conventional dosage forms due to swallowing challenges, metabolic differences, or adherence issues. Spurred by this need, innovations such as orally disintegrating tablets, chewable forms, and sustained-release systems are gaining traction. Pharmaceutical companies are actively leveraging patient-centric formulation strategies to tap into this segment. This demographic-driven shift is poised to accelerate adoption and market growth.

Threat:

Pediatric and geriatric applications surge

A key threat to the market stems from frequent patent expirations, opening the door for generic drug manufacturers to enter aggressively. This intensifies price competition and reduces the profit margins for branded advanced formulations. Moreover, generic alternatives often gain rapid acceptance due to affordability, especially in cost-sensitive regions. Spurred by these dynamics, innovative firms must continuously reinvest in pipeline development. Failure to differentiate with novel formulations risks market share erosion, threatening long-term sustainability of branded players.

Covid-19 Impact:

The COVID-19 pandemic had a dual impact on the advanced drug formulation market. On one hand, disruptions in global supply chains and delayed clinical trials hindered R&D progress. On the other, the crisis accelerated demand for innovative drug delivery methods, particularly in vaccines and antiviral therapies. Companies adopted mRNA formulations and novel delivery systems at unprecedented speed, setting new benchmarks for efficiency. This transformative phase underscored the importance of advanced formulations in addressing global health emergencies and beyond.

The oral segment is expected to be the largest during the forecast period

The oral segment is expected to account for the largest market share during the forecast period, driven by patient convenience, high compliance, and cost-effectiveness. Advanced formulations such as extended-release tablets, orally disintegrating tablets, and nano-enabled oral drugs are strengthening this segment's market position. The surge in chronic disease therapies delivered orally further enhances its adoption. Pharmaceutical firms are prioritizing innovations in this route to maximize therapeutic efficacy. Consequently, the oral segment is projected to secure the largest market share in the coming years.

The biologics segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the biologics segment is predicted to witness the highest growth rate, due to rising demand for targeted therapies, monoclonal antibodies, and cell-based treatments. These complex molecules require sophisticated formulation strategies to maintain stability, efficacy, and controlled release. Propelled by advancements in biotechnology and precision medicine, the biologics segment is gaining strong momentum. Ongoing investments in biosimilars and next-generation biologics will further fuel expansion. As a result, this segment is expected to record the highest CAGR in the forecast horizon.

Region with largest share:

During the forecast period, the Asia Pacific region is expected to hold the largest market share, attributed to rising healthcare expenditures, a large patient pool, and rapid pharmaceutical manufacturing expansion. Countries such as China, India, and Japan are strengthening their R&D infrastructure and attracting global investments. Furthermore, increasing prevalence of lifestyle-related diseases and supportive government initiatives enhance adoption of advanced formulations. Collectively, these factors solidify Asia Pacific's dominance in the advanced drug formulation landscape.

Region with highest CAGR:

Over the forecast period, the North America region is anticipated to exhibit the highest CAGR fueled by robust innovation, advanced healthcare infrastructure, and strong regulatory frameworks supporting new formulations. The region is home to leading pharmaceutical and biotech companies investing in next-generation drug delivery technologies. Moreover, rising demand for biologics, coupled with high chronic disease incidence, accelerates adoption. Supportive reimbursement policies and rapid uptake of premium therapies further boost growth. Consequently, North America will be the fastest-growing regional market.

Key players in the market

Some of the key players in Advanced Drug Formulation Market include AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Gilead Sciences, Merck & Co., Novartis, Pfizer, AbbVie, Boehringer Ingelheim, F. Hoffmann-La Roche, Bayer, Sanofi, Amgen, Celgene, Johnson & Johnson, and Regeneron Pharmaceuticals.

Key Developments:

In Aug 2025, AstraZeneca unveiled a breakthrough nanoparticle-based inhalable asthma therapy, engineered for rapid onset and enhanced pulmonary deposition. This innovation targets chronic respiratory patients, ensuring superior drug delivery efficiency, faster symptom relief, and improved long-term disease management outcomes.

In July 2025, Pfizer introduced an advanced dual-release oral capsule for rheumatoid arthritis, combining immediate and sustained release mechanisms. This novel design improves patient adherence, minimizes disease flare-ups, and ensures consistent therapeutic control, enhancing long-term outcomes for chronic arthritis sufferers.

In June 2025, Novartis launched a pioneering temperature-stable injectable biologic for oncology, formulated to withstand challenging storage conditions. By extending shelf life and eliminating cold-chain dependence, it broadens accessibility, particularly in low-resource settings, ensuring reliable cancer care worldwide.

Formulation Types Covered:

  • Oral
  • Injectable
  • Topical
  • Transdermal
  • Inhalation
  • Nasal
  • Implantable

Drug Types Covered:

  • Small Molecules
  • Biologics
  • Vaccines
  • Peptides
  • Nucleic Acid-Based
  • Biosimilars
  • Generic Drugs

Therapeutic Areas Covered:

  • Oncology
  • Cardiovascular
  • Neurology
  • Infectious Diseases
  • Immunology
  • Endocrinology
  • Rare Diseases

Technologies Covered:

  • Nanotechnology
  • Liposomal Delivery
  • Sustained Release
  • Controlled Release
  • Targeted Delivery
  • Solid Dispersions

End Users Covered:

  • Hospitals
  • Pharmaceutical Companies
  • Biotechnology Firms
  • Research Laboratories
  • Clinics
  • Contract Research Organizations
  • Academic Institutions

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Technology Analysis
  • 3.7 End User Analysis
  • 3.8 Emerging Markets
  • 3.9 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Advanced Drug Formulation Market, By Formulation Type

  • 5.1 Introduction
  • 5.2 Oral
  • 5.3 Injectable
  • 5.4 Topical
  • 5.5 Transdermal
  • 5.6 Inhalation
  • 5.7 Nasal
  • 5.8 Implantable

6 Global Advanced Drug Formulation Market, By Drug Type

  • 6.1 Introduction
  • 6.2 Small Molecules
  • 6.3 Biologics
  • 6.4 Vaccines
  • 6.5 Peptides
  • 6.6 Nucleic Acid-Based
  • 6.7 Biosimilars
  • 6.8 Generic Drugs

7 Global Advanced Drug Formulation Market, By Therapeutic Area

  • 7.1 Introduction
  • 7.2 Oncology
  • 7.3 Cardiovascular
  • 7.4 Neurology
  • 7.5 Infectious Diseases
  • 7.6 Immunology
  • 7.7 Endocrinology
  • 7.8 Rare Diseases

8 Global Advanced Drug Formulation Market, By Technology

  • 8.1 Introduction
  • 8.2 Nanotechnology
  • 8.3 Liposomal Delivery
  • 8.4 Sustained Release
  • 8.5 Controlled Release
  • 8.6 Targeted Delivery
  • 8.7 Solid Dispersions

9 Global Advanced Drug Formulation Market, By End User

  • 9.1 Introduction
  • 9.2 Hospitals
  • 9.3 Pharmaceutical Companies
  • 9.4 Biotechnology Firms
  • 9.5 Research Laboratories
  • 9.6 Clinics
  • 9.7 Contract Research Organizations
  • 9.8 Academic Institutions

10 Global Advanced Drug Formulation Market, By Geography

  • 10.1 Introduction
  • 10.2 North America
    • 10.2.1 US
    • 10.2.2 Canada
    • 10.2.3 Mexico
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 Italy
    • 10.3.4 France
    • 10.3.5 Spain
    • 10.3.6 Rest of Europe
  • 10.4 Asia Pacific
    • 10.4.1 Japan
    • 10.4.2 China
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 New Zealand
    • 10.4.6 South Korea
    • 10.4.7 Rest of Asia Pacific
  • 10.5 South America
    • 10.5.1 Argentina
    • 10.5.2 Brazil
    • 10.5.3 Chile
    • 10.5.4 Rest of South America
  • 10.6 Middle East & Africa
    • 10.6.1 Saudi Arabia
    • 10.6.2 UAE
    • 10.6.3 Qatar
    • 10.6.4 South Africa
    • 10.6.5 Rest of Middle East & Africa

11 Key Developments

  • 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 11.2 Acquisitions & Mergers
  • 11.3 New Product Launch
  • 11.4 Expansions
  • 11.5 Other Key Strategies

12 Company Profiling

  • 12.1 AstraZeneca
  • 12.2 Bristol-Myers Squibb
  • 12.3 Eli Lilly
  • 12.4 Gilead Sciences
  • 12.5 Merck & Co.
  • 12.6 Novartis
  • 12.7 Pfizer
  • 12.8 AbbVie
  • 12.9 Boehringer Ingelheim
  • 12.10 F. Hoffmann-La Roche
  • 12.11 Bayer
  • 12.12 Sanofi
  • 12.13 Amgen
  • 12.14 Celgene
  • 12.15 Johnson & Johnson
  • 12.16 Regeneron Pharmaceuticals

List of Tables

  • Table 1 Global Advanced Drug Formulation Market Outlook, By Region (2024-2032) ($MN)
  • Table 2 Global Advanced Drug Formulation Market Outlook, By Formulation Type (2024-2032) ($MN)
  • Table 3 Global Advanced Drug Formulation Market Outlook, By Oral (2024-2032) ($MN)
  • Table 4 Global Advanced Drug Formulation Market Outlook, By Injectable (2024-2032) ($MN)
  • Table 5 Global Advanced Drug Formulation Market Outlook, By Topical (2024-2032) ($MN)
  • Table 6 Global Advanced Drug Formulation Market Outlook, By Transdermal (2024-2032) ($MN)
  • Table 7 Global Advanced Drug Formulation Market Outlook, By Inhalation (2024-2032) ($MN)
  • Table 8 Global Advanced Drug Formulation Market Outlook, By Nasal (2024-2032) ($MN)
  • Table 9 Global Advanced Drug Formulation Market Outlook, By Implantable (2024-2032) ($MN)
  • Table 10 Global Advanced Drug Formulation Market Outlook, By Drug Type (2024-2032) ($MN)
  • Table 11 Global Advanced Drug Formulation Market Outlook, By Small Molecules (2024-2032) ($MN)
  • Table 12 Global Advanced Drug Formulation Market Outlook, By Biologics (2024-2032) ($MN)
  • Table 13 Global Advanced Drug Formulation Market Outlook, By Vaccines (2024-2032) ($MN)
  • Table 14 Global Advanced Drug Formulation Market Outlook, By Peptides (2024-2032) ($MN)
  • Table 15 Global Advanced Drug Formulation Market Outlook, By Nucleic Acid-Based (2024-2032) ($MN)
  • Table 16 Global Advanced Drug Formulation Market Outlook, By Biosimilars (2024-2032) ($MN)
  • Table 17 Global Advanced Drug Formulation Market Outlook, By Generic Drugs (2024-2032) ($MN)
  • Table 18 Global Advanced Drug Formulation Market Outlook, By Therapeutic Area (2024-2032) ($MN)
  • Table 19 Global Advanced Drug Formulation Market Outlook, By Oncology (2024-2032) ($MN)
  • Table 20 Global Advanced Drug Formulation Market Outlook, By Cardiovascular (2024-2032) ($MN)
  • Table 21 Global Advanced Drug Formulation Market Outlook, By Neurology (2024-2032) ($MN)
  • Table 22 Global Advanced Drug Formulation Market Outlook, By Infectious Diseases (2024-2032) ($MN)
  • Table 23 Global Advanced Drug Formulation Market Outlook, By Immunology (2024-2032) ($MN)
  • Table 24 Global Advanced Drug Formulation Market Outlook, By Endocrinology (2024-2032) ($MN)
  • Table 25 Global Advanced Drug Formulation Market Outlook, By Rare Diseases (2024-2032) ($MN)
  • Table 26 Global Advanced Drug Formulation Market Outlook, By Technology (2024-2032) ($MN)
  • Table 27 Global Advanced Drug Formulation Market Outlook, By Nanotechnology (2024-2032) ($MN)
  • Table 28 Global Advanced Drug Formulation Market Outlook, By Liposomal Delivery (2024-2032) ($MN)
  • Table 29 Global Advanced Drug Formulation Market Outlook, By Sustained Release (2024-2032) ($MN)
  • Table 30 Global Advanced Drug Formulation Market Outlook, By Controlled Release (2024-2032) ($MN)
  • Table 31 Global Advanced Drug Formulation Market Outlook, By Targeted Delivery (2024-2032) ($MN)
  • Table 32 Global Advanced Drug Formulation Market Outlook, By Solid Dispersions (2024-2032) ($MN)
  • Table 33 Global Advanced Drug Formulation Market Outlook, By End User (2024-2032) ($MN)
  • Table 34 Global Advanced Drug Formulation Market Outlook, By Hospitals (2024-2032) ($MN)
  • Table 35 Global Advanced Drug Formulation Market Outlook, By Pharmaceutical Companies (2024-2032) ($MN)
  • Table 36 Global Advanced Drug Formulation Market Outlook, By Biotechnology Firms (2024-2032) ($MN)
  • Table 37 Global Advanced Drug Formulation Market Outlook, By Research Laboratories (2024-2032) ($MN)
  • Table 38 Global Advanced Drug Formulation Market Outlook, By Clinics (2024-2032) ($MN)
  • Table 39 Global Advanced Drug Formulation Market Outlook, By Contract Research Organizations (2024-2032) ($MN)
  • Table 40 Global Advanced Drug Formulation Market Outlook, By Academic Institutions (2024-2032) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above. Introduction